logo
Share SHARE
FONT-SIZE Plus   Neg

Ranbaxy Obtains Approval To Market Ran-Rosuvastatin In Canada - Quick Facts

Ranbaxy Pharmaceuticals Canada Inc. or RPCI, a wholly owned subsidiary of Ranbaxy Laboratories Limited, announced that RPCI has received approval from Health Canada to manufacture and market RAN-Rosuvastatin tablets to the Canadian healthcare system. Rosuvastatin is a HMG-COA Reductase Inhibitor (cholesterol-lowering medication). Brand sales of Crestorin Canada were $742.2 million.

"The finished dosage form was developed, and will be manufactured within RLL's Health Canada approved facilities located in India. We anticipate making Rosuvastatin tablets available to all classes of trade after April 2 when sufficient supplies are available to meet market demand," said Paul Drake, President and General Manager of RPCI.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Struggling fast-food giant McDonald's is trying to woo back customers to its stores with a new concept called "Experience of the Future." According to reports, as part of its "Experience of the Future" initiative McDonald's is planning to upgrade and renovate its restaurants that will provide modern... Facebook might be launching smart speakers with a touch panel next year. The touch screen could be used for 15-inch display of imageries. According to reports Facebook has already begun the pilot production in China. The new device is expected to be launched in the first quarter of 2018. Britain is the latest nation to announce that it will end the sale of new petrol and diesel cars in an effort to reduce air pollution. Britain said it will ban the sale of new petrol and diesel cars from 2040. In early July, France said it plans to end sales of all petrol and diesel vehicles in the country by 2040 as part of a plan to meet its targets under the Paris climate accord.
comments powered by Disqus
Follow RTT